/

Other

/

Intra-Cellular Therapies

Intra-Cellular Therapies

Intra-Cellular Therapies

Verified Nov 2026

Other

·

United States flag

New York, New York

·

Since 2002

Intra-Cellular Therapies is a biopharmaceutical company headquartered in New York, founded in 2002, with 500–1,000 employees and estimated revenue between $500 million and $1 billion. The company discovers and develops small-molecule treatments for central nervous system and neuropsychiatric disorders. Its approved product CAPLYTA treats schizophrenia and bipolar depression, while its pipeline addresses generalized anxiety disorder, Alzheimer's agitation, and Parkinson's disease. Johnson & Johnson acquired the company in 2025.

Intra-Cellular Therapies

Verified Nov 2026

AT A GLANCE

Founded

2002

Headquarters

United States flag

New York, New York

Employees

500-1,000

Ownership

Intra-Cellular Therapies at a glance

Revenue

$500M-1B

Est. band

Employees

500-1,000

Founded

2002

Headquarters

New York, New York

Industries

Automotive

Electric Vehicles

Medical

Overview

Intra-Cellular Therapies is a biopharmaceutical company headquartered in New York, founded in 2002, with 500–1,000 employees and estimated revenue between $500 million and $1 billion. The company discovers and develops small-molecule treatments for central nervous system and neuropsychiatric disorders. Its approved product CAPLYTA treats schizophrenia and bipolar depression, while its pipeline addresses generalized anxiety disorder, Alzheimer's agitation, and Parkinson's disease. Johnson & Johnson acquired the company in 2025.

At a glance

Attribute

Detail

Founded

2002

Headquarters

New York, New York

Employees

500-1,000

Revenue

$500M-1B (estimated)

What Intra-Cellular Therapies makes

The company employs a proprietary CNSProfile technology platform to validate and select drug candidates, and has built a pipeline of investigational small-molecule compounds targeting multiple neurologic conditions.

Latest developments

Company details

Intra-Cellular Therapies was founded on research by Nobel laureate Dr. Paul Greengard and operates within the biopharmaceutical and healthcare sectors, with particular focus on psychiatric and neurodegenerative diseases. Intra-Cellular Therapies was founded in 2002, has an estimated 500-1,000 employees, and is headquartered in New York, New York.

Frequently asked questions

What does Intra-Cellular Therapies do?

Intra-Cellular Therapies is a biopharmaceutical company headquartered in New York, founded in 2002, with 500–1,000 employees and estimated revenue between $500 million and $1 billion. The company discovers and develops small-molecule treatments for central nervous system and neuropsychiatric disorders. Its approved product CAPLYTA treats schizophrenia and bipolar depression, while its pipeline addresses generalized anxiety disorder, Alzheimer's agitation, and Parkinson's disease. Johnson & Johnson acquired the company in 2025.

Where is Intra-Cellular Therapies headquartered?

Intra-Cellular Therapies is headquartered in New York, New York (430 East 29th Street, New York, New York, 10016).

When was Intra-Cellular Therapies founded?

Intra-Cellular Therapies was founded in 2002.

How big is Intra-Cellular Therapies?

Intra-Cellular Therapies has an estimated 500-1,000 employees, with revenue in the $500M-1B range (estimated).

Related suppliers

Explore other suppliers in the LightSource directory:

Last verified Nov 2026. Is this your company? Request a correction.

Location & contact

New York, New York (HQ)Headquarters · United States
New York, New York (HQ)430 East 29th Street, New York, New York, 10016, United StatesHeadquarters

Evaluating suppliers like these?

This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.